Evidence map›Paper›PMID 26644206›Full record

ArticleThe pharmacogenomics journal2017

Effect of gene polymorphims on the warfarin treatment at initial stage.

J Liu, H H Jiang, D K Wu, Y X Zhou, H M Ye, X Li, Z Y Luo, Z Guo, Y L Zhang, Y C Wang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Pharmacogenomics Informs Cardiovascular Pharmacotherapy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

J LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
H H JiangDepartment of Cardiothoracic Surgery, Xiangya Hospital, Central South University, Changsha, China.
D K WuDepartment of Cardiothoracic Surgery, Xiangya Hospital, Central South University, Changsha, China.
Y X ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
H M YeDepartment of Clinical Laboratory, Zhongshan Hospital Xiamen University Translational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.
X LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Z Y LuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Z GuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Y L ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Y C WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
W ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
H H ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
L S WangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CNZhongshan Hospital of Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The adverse reactions of warfarin that were found mainly occurred in the first month. This study was carried out to observe the effect of gene polymorphisms on the warfarin therapy at the initial stage. Four-hundred and sixty Chinese patients began warfarin treatment with daily 2.5 mg after heart valve replacement operations were enrolled. The daily international normalized ratio (INR) for anticoagulation were recorded till the seventh day. Blood samples were collected and used to detect genotypes for VKORC1 rs7294, CYP2C9 rs1057910, CYP4F2 rs2108622 and ORM1 rs17650. INR and their changes were compared among genotypes. INR was partially correlated with the VKORC1 rs7294, CYP2C9 rs1057910, CYP4F2 rs2108622 and ORM1 rs17650 polymorphisms from the third, fourth and sixth day on, respectively. VKORC1 rs7294 and CYP4F2 rs2108622 carriers responded lower than the wild genotype, whereas CYP2C9 rs1057910 and ORM1 rs17650 carriers responded higher, respectively. Fifty percent of AA/*1*3/CC/*S*S patients and 16% of AA/*1*1/CC/*S*S patients were over anticoagulation treated with INR >4.0 at the third day. Ninety percent of VKORC1 rs7294 carrier patients have INR <1.63, a mark of the 25% of lower responders of the wild genotype. Our study provided another kind of evidence that VKORC1 rs7294, CYP2C9 rs1057910, CYP4F2 rs2108622 and ORM1 rs17650 affected the action of warfarin in different styles. Patients with AA/*1*1/CC/*S*S, AA/*1*3/CC/*S*S should use a less initial dosage to avoid over anticoagulation, and patients with VKORC1 rs7294 should use larger initial dose to proof an effective therapy.

Indexed as

Pharmacogenomic VariantsAdministration, OralAdolescentAdultAgedAnticoagulantsBlood CoagulationChinaCytochrome P-450 CYP2C9Cytochrome P450 Family 4Drug Dosage CalculationsDrug MonitoringFemaleGene FrequencyGenotypeHeart Valve Prosthesis ImplantationAnticoagulantsCYP2C9 protein, humanCYP4F2 protein, humanCytochrome P-450 CYP2C9Cytochrome P450 Family 4OrosomucoidVitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID26644206
OpenAlexW2191939439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.